Alpha Cognition (NASDAQ:ACOG – Get Free Report) and Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
Analyst Ratings
This is a summary of recent ratings for Alpha Cognition and Zentalis Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Cognition | 0 | 0 | 2 | 0 | 3.00 |
| Zentalis Pharmaceuticals | 1 | 4 | 1 | 1 | 2.29 |
Alpha Cognition currently has a consensus target price of $16.00, indicating a potential upside of 162.30%. Zentalis Pharmaceuticals has a consensus target price of $5.83, indicating a potential upside of 32.28%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, research analysts plainly believe Alpha Cognition is more favorable than Zentalis Pharmaceuticals.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Cognition | $10.22 million | 12.99 | -$20.67 million | ($1.16) | -5.26 |
| Zentalis Pharmaceuticals | $67.43 million | 4.66 | -$137.06 million | ($1.90) | -2.32 |
Alpha Cognition has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Alpha Cognition is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Alpha Cognition and Zentalis Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Cognition | -202.23% | -55.71% | -43.78% |
| Zentalis Pharmaceuticals | N/A | -52.77% | -40.55% |
Risk & Volatility
Alpha Cognition has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.
Summary
Alpha Cognition beats Zentalis Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
